Table 7.
Sensitivity Analysis I: The Risk of Unfavorable Functional Outcomes and SICH With AF
| Characteristics | AF | Non‐AF | After IPTW | |||
|---|---|---|---|---|---|---|
| RR (95% CI) | P value | Adjusted RR (95% CI)* | P value | |||
| Functional outcome of mRS at 90 d | ||||||
| 0: No symptoms | 13.1% (128/980) | 17.9% (245/1371) | ||||
| 1: No substantive disability | 14.0% (137/980) | 16.8% (230/1371) | ||||
| 2: Slight disability | 11.5% (113/980) | 12.0% (165/1371) | ||||
| 3: Moderate disability | 11.4% (112/980) | 15.7% (215/1371) | ||||
| 4: Moderate to severe disability | 19.5% (191/980) | 17.7% (243/1371) | ||||
| 5: Severe disability | 20.7% (203/980) | 11.9% (163/1371) | ||||
| 6: Death | 9.8% (96/980) | 8.0% (110/1371) | 1.12 (0.92–1.37) | 0.2618 | 0.99 (0.73–1.33) | 0.9258 |
| Favorable outcomes at 90 d | ||||||
| mRS of 0–1, FFO | 27.4% (268/980) | 34.9% (479/1371) | 1.03 (0.96–1.10) | 0.4244 | 0.97 (0.87–1.07) | 0.5077 |
| mRS of 0–2, FI | 38.5% (377/980) | 47.0% (644/1371) | 1.04 (0.96–1.12) | 0.3046 | 0.97 (0.87–1.09) | 0.6430 |
| SICH at 24–36 h | ||||||
| By NINDS standard | 5.8% (57/980) | 2.4% (33/1371) | 2.00 (1.47–2.74) | <0.0001 * | 2.14 (1.36–3.37) | 0.0010 * |
| By ECASS II standard | 3.0% (29/980) | 1.8% (24/1371) | 1.32 (0.89–1.95) | 0.1680 | 1.43 (0.81–2.54) | 0.2145 |
| By SITS‐MOST standard | 1.2% (12/980) | 1.0% (14/1371) | 0.90 (0.51–1.61) | 0.7331 | 0.99 (0.44–2.20) | 0.9726 |
AF indicates atrial fibrillation; ECASS II, European Cooperative Acute Stroke Study II; FFO, favorable functional outcome; FI, functional independence; IPTW, inverse probability of treatment weighting; mRS, modified Rankin Scale; NINDS, National Institute of Neurological Disorders and Stroke; RR, relative risk; SICH, symptomatic intracranial hemorrhage; and SITS‐MOST, Safe Implementation of Thrombolysis in Stroke‐Monitoring Study.
Multivariable Poisson regression was adjusted for fixed effects of the THRIVE (Totaled Health Risks in Vascular Events) score, prestroke mRS, early ischemic changes, and use of antithrombotic medications, and random effects for 30 hospitals.
Statistically significant at P<0.05.